
Alzheimer's Disease Treatment Selection: Anti-Amyloid Uptake and Stage-Based Care
Population prevalence, treatment hesitancy, and modest slowing of decline shape who receives anti-amyloid therapy today. Management differs sharply across the six stages, from clinical trials and lifestyle changes to comprehensive caregiver-centered care.
This episode, "Alzheimer's Disease Treatment Selection: Anti-Amyloid Uptake and Stage-Based Care," finds Dr. Reuben examining who should be tested, who is actually receiving disease-modifying therapy, and how care changes at each stage.
Dr. Reuben notes that overall prevalence of preclinical Alzheimer's is about 20%, which means about 80% of cognitively unimpaired people do not have it. He expects this picture to change within a year or so. A more accurate plasma biomarker, not yet commercially available, correlates better with tau PET.
For now, the next step is determining whether a person has cognitive impairment. If they do, whether mild or early dementia, the discussion turns to disease-modifying anti-amyloid therapy. He was surprised to learn at the Alzheimer's Association International Conference that only about 25,000 to 30,000 people are on these drugs.
In his own practice, many patients decline. They fear amyloid-related imaging abnormalities such as edema or hemorrhage, dislike infusions, and doubt the benefit. Published studies show roughly 25% to 30% slowing of progression, which means the drugs slow the disease rather than turn it off.
Dr. Reuben then explains that approaches differ across the six stages. Cognitively unimpaired people may be good candidates for the roughly 150 drugs in active research, and for lifestyle changes. The U.S. POINTER study supports attention to cardiovascular risk, exercise, Mediterranean-type diets, and cognitive training. Mild cognitive impairment and early dementia call for a conversation about approved drugs.
About 85% of people with Alzheimer's disease are in dementia stages, where cholinesterase inhibitors and memantine are generic and widely used. Comprehensive care matters most here. Caregivers are the most valuable resource, and empowered caregivers produce better care. Advanced disease is beyond disease-modifying therapy, since these drugs cannot bring back lost neurons.
Our next segment, "Late-Stage Alzheimer's Disease: Individualized Caregiving and Caregiver Support," features Dr. Reuben sharing two contrasting patient stories as he describes what good care looks like in later disease.
Related to this article








